(Report ID: 78042) Many drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 21, 2008, eHealthMe analyzes 10,180,650 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 21, 2008: 3,644 relevant incidents
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 78042 | Mar, 24, 2006 | 52 | Male |
List of drugs the patient takes:
| Drug |
Cyclosporine |
Prednisolone |
| Name |
Amyotrophy |
Areflexia |
Asthenia |
Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
Csf Protein Increased |
Difficulty In Walking |
Lymphoma |
Muscle Atrophy |
Paraesthesia |
Sensorimotor Disorder |
Results from eHealthMe: 3,644 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Amyotrophy | 1 (0.03%) |
Areflexia | 9 (0.25%) |
Asthenia | 29 (0.80%) |
Chronic Inflammatory Demyelinating Polyradiculoneuropathy | 6 (0.16%) |
Csf Protein Increased | 16 (0.44%) |
Difficulty In Walking | 17 (0.47%) |
Lymphoma | 15 (0.41%) |
Muscle Atrophy | 8 (0.22%) |
Paraesthesia | 26 (0.71%) |
Sensorimotor Disorder | 6 (0.16%) |
Death: 2 (0.95% of total reports)
Cancer: 1 (0.47% of total reports)
| Name | Count (% of total reports) |
1 | Blood Creatinine Increased | 22 (10.43%) |
2 | Renal Impairment | 18 (8.53%) |
3 | Renal Failure | 17 (8.06%) |
4 | Pyrexia | 17 (8.06%) |
5 | Proteinuria | 13 (6.16%) |
6 | Cytomegalovirus Infection | 13 (6.16%) |
7 | Nephrotic Syndrome | 13 (6.16%) |
8 | Diarrhoea | 10 (4.74%) |
9 | Kidney Transplant Rejection | 10 (4.74%) |
10 | Haemoglobin Decreased | 10 (4.74%) |
3) Top co-used drugs drugs reported for the past 12 months:
| Name | Count |
1 | Mycophenolate Mofetil | 72 |
2 | Neoral | 66 |
3 | Azathioprine | 37 |
4 | Methotrexate | 34 |
5 | Sandimmune | 21 |
6 | Tacrolimus | 15 |
7 | Cyclophosphamide | 15 |
8 | Cellcept | 13 |
9 | Acyclovir | 10 |
10 | Myfortic | 10 |
Death: 36 (0.99% of total reports)
Cancer: 80 (2.20% of total reports)
| Name | Count (% of total reports) |
1 | Pyrexia | 428 (11.75%) |
2 | Blood Creatinine Increased | 302 (8.29%) |
3 | Cytomegalovirus Infection | 239 (6.56%) |
4 | Kidney Transplant Rejection | 167 (4.58%) |
5 | Graft Versus Host Disease | 155 (4.25%) |
6 | Condition Aggravated | 151 (4.14%) |
7 | Pneumonia Nos | 143 (3.92%) |
8 | Renal Impairment | 134 (3.68%) |
9 | Thrombocytopenia | 130 (3.57%) |
10 | Haemoglobin Decreased | 130 (3.57%) |
| Name | Count |
1 | Neoral | 1,500 |
2 | Azathioprine | 785 |
3 | Sandimmune | 737 |
4 | Mycophenolate Mofetil | 378 |
5 | Methotrexate | 360 |
6 | Cellcept | 284 |
7 | Furosemide | 236 |
8 | Ranitidine | 218 |
9 | Cyclophosphamide | 209 |
10 | Rapamune | 202 |
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|
